RNS Number:1683J
Galen Holdings PLC
25 March 2003

                                                           FOR IMMEDIATE RELEASE



25 March 2003





                               GALEN HOLDINGS PLC
 PROPOSED ACQUISITION OF WOMEN'S HEALTHCARE PRODUCTS PORTFOLIO FROM PFIZER INC.
                    RESULT OF EXTRAORDINARY GENERAL MEETING


Craigavon, Northern Ireland, UK / Rockaway, New Jersey, US:  Galen Holdings PLC
(LSE: GAL, Nasdaq: GALN) (the "Company" or "Galen"), the international
pharmaceutical company, announces today that, at the extraordinary general
meeting of the Company held at 12 noon, the resolutions approving the
acquisition by Galen of the women's healthcare pharmaceutical brands comprising
the oral contraceptives Estrostep(R) and Loestrin(R) and the hormone replacement
therapy, femhrt(R) (together the "Pfizer Portfolio"), were duly passed.  Further
details of the proposed acquisition of the Pfizer Portfolio are set out in the
Company's announcement and circular to shareholders, each dated 6 March 2003.



Following receipt of the requisite US regulatory clearances on 20 March 2003,
completion of the acquisition of the oral contraceptives Estrostep(R) and
Loestrin(R) is expected to be on  27 March 2003.



Completion of the acquisition of the hormone replacement therapy femhrt(R)
remains conditional upon clearance from the US Federal Trade Commission of the
merger between Pfizer Inc. and Pharmacia Corp.



                                  #    #    #





ENQUIRIES:


Galen Holdings PLC
David Kelly                                               Tel: + 44 283 833 4974
Senior Vice President Finance & Planning


Hoare Govett Limited
Andrew Chapman/Justin Jones                               Tel: +44 20 7678 8000


Financial Dynamics
Sophie Pender-Cudlip/Francetta Carr                       Tel: + 44 20 7831 3113





For further information on Galen, please visit www.galenplc.com



Forward looking statements in this report, including, without limitation,
statements relating to the Galen''s plans, strategies, objectives, expectations,
intentions and adequacy of resources, are made pursuant to the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These
forward looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or achievements of
Galen to be materially different from any future results, performance or
achievements expressed or implied by such forward looking statements. These
factors include, among others, the following: Galen's ability to manage its
growth, government regulation affecting the development, manufacture, marketing
and sale of pharmaceutical products, customer acceptance of new products,
competitive factors in the industries in which Galen operates, the loss of key
senior management or scientific staff, exchange rate fluctuations, general
economic and business conditions, and other factors described in filings of the
Galen with the SEC. Galen undertakes no obligation to publicly update or revise
any forward looking statement, whether as a result of new information, future
events or otherwise.



Hoare Govett Limited, which is authorised and regulated in the UK by the
Financial Services Authority, is acting for Galen Holdings PLC and no one else
in connection with the matters set out in this announcement and will not be
responsible to anyone other than Galen Holdings PLC for providing the
protections afforded to the clients of Hoare Govett Limited or for providing
advice in relation to the matters set out in this announcement or any
transaction referred to herein.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EGMILFIVVEIEFIV